Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC -CAR T cell efficacy in localized neuroblastoma
- Quaovi H. Sodji
- Amanda Shea
- Dan Cappabianca
- Matthew H. Forsberg
- Jens C. Eickhoff
- Malick Bio Idrissou
- Andy S. Ollendorff
- Ohyun Kwon
- Irene M. Ong
- Reinier Hernandez
- Jamey Weichert
- Bryan P. Bednarz
- Krishanu Saha
- Paul M. Sondel
- Christian M. Capitini
- Zachary S. Morris
2025-06-11
Chimeric antigen receptor (CAR) T cells have limited efficacy against solid tumors including neuroblastoma. Here, we evaluated whether low-dose radiation delivered by radiopharmaceutical therapy (RPT), known to potentiate immune checkpoint inhibitors, can synergize with CRISPR-edited GD2 TRAC- CAR T cells to improve outcomes in neuroblastoma. We found that in the localized model of neuroblastoma, low-dose radiation delivered by 177 Lu-NM600, an alkylphosphocholine mimetic RPT agent, followed 9 days later by GD2 TRAC- CAR T cells led to complete tumor regression. Irradiation of neuroblastoma before GD2 TRAC- CAR T cells enhanced the release by CAR T cells of perforin, granzyme B, tumor necrosis factor–α, and interleukin-7 while abrogating transforming growth factor–β1. Low-dose RPT up-regulated the death receptor Fas on neuroblastoma, potentially enabling CAR-independent killing. This suggests that low-dose RPT can enhance suboptimal CAR T cell efficacy against solid tumors. However, optimization of radiation dose and timing may be needed for each patient and RPT agent to account for varied tumor radiosensitivity and dosimetry.